Moreover, IL12B was the single prognostic cytokine with low expression that led to shorter RFS of KRASwt LUAD patients, increasing living risks before tumor recurrence by 1.57 times (HR = 0.638, 95% CI = 0.442–0.921, and p = 0.0166 for the high vs. low IL12B expression KRASwt subgroup, Fig. 5F). The gene discussed is IL12B; the disease is neoplasm.